Operationalization of the test and not treat strategy to accelerate the elimination of onchocerciasis and lymphatic filariasis in Central Africa

International Health
Joseph KamgnoMichel Boussinesq

Abstract

After 30 years of treatment with Mectizan (ivermectin), cutaneous and ocular complications of Onchocerca volvulus infection are now scarce in endemic communities. Indeed, transmission has been interrupted and the O. volvulus- associated disease has disappeared in some African foci. Despite this success, onchocerciasis elimination in Loa loa co-endemic areas is still constrained by severe adverse events (SAEs) occurring after ivermectin treatment in some individuals harbouring very high L. loa microfilaremia. One approach towards the prevention of these SAEs is to identify individuals with high L. loa microfilaremia and exclude them from ivermectin treatment. The development of the LoaScope has provided the tool that underlies this test and not treat (TaNT) strategy. The first successful TaNT campaign was conducted in a L. loa highly endemic focus in Cameroon in 2015 without any SAEs. To accomplish this within a research setting, 60 people were deployed for this campaign, making this 'research' strategy not sustainable from a cost perspective. We describe here a way of reducing the cost of the TaNT strategy with a smaller team (three people) selected within affected communities. We also suggest the organization of a TaNT campaig...Continue Reading

References

Jul 1, 1993·The Journal of Infectious Diseases·A D KlionT B Nutman
Feb 17, 1998·Transactions of the Royal Society of Tropical Medicine and Hygiene·J GardonM Boussinesq
Apr 10, 2002·Parasite : Journal De La Société Française De Parasitologie·J Kamgno, M Boussinesq
Jan 23, 2003·Annals of Tropical Medicine and Parasitology·L Tsague-DongmoM Boussinesq
Mar 9, 2010·The American Journal of Tropical Medicine and Hygiene·Joseph KamgnoMichel Boussinesq
Jul 10, 2010·Bulletin of the World Health Organization·UNKNOWN CDI Study Group
Nov 15, 2011·Trends in Parasitology·Charles D MackenzieJoni C Lawrence
May 8, 2015·Science Translational Medicine·Michael V D'AmbrosioDaniel A Fletcher
Nov 4, 2016·The American Journal of Tropical Medicine and Hygiene·Isam M A ZarrougTarig B Higazi
Nov 9, 2017·The New England Journal of Medicine·Joseph KamgnoMichel Boussinesq

❮ Previous
Next ❯

Citations

Feb 23, 2018·International Health·Joni Lawrence, Yao K Sodahlon
Jun 6, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Edeltraud J LenkWilma A Stolk
Sep 13, 2019·Molecular Biology Reports·Natarajan MahalakshmiSankaranarayanan Meenakshisundaram
Jul 16, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Natalie V S Vinkeles MelchersWilma A Stolk
Nov 16, 2019·Gates Open Research·UNKNOWN NTD Modelling Consortium Lymphatic Filariasis Group
Sep 23, 2020·The American Journal of Tropical Medicine and Hygiene·Lindsay J RakersFrank O Richards
Dec 9, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David J BlokWilma A Stolk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.